Pelabresib
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for Pelabresib, covering 2024-10-28 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) [Phase 3]